Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Oncothyreon Inc (NASDAQ:ONTY)

3.25
Delayed Data
As of Sep 04
 -0.10 / -2.99%
Today’s Change
1.41
Today|||52-Week Range
4.69
+71.05%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$308.5M

Company Description

Oncothyreon, Inc. is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. Its current clinical-stage product candidates include ONT-380, an orally active and selective small-molecule HER2 inhibitor, and ONT-10, a therapeutic vaccine targeting the Mucin 1 peptide antigen. The company was founded on September 7, 2007 and is headquartered in Seattle, WA.

Contact Information

Oncothyreon, Inc.
2601 4th Avenue
Seattle Washington 98121
P:(206) 801-2100
Investor Relations:

Employees

Shareholders

Other institutional42.29%
Mutual fund holders19.50%
Individual stakeholders14.93%

Top Executives

Robert L. KirkmanPresident, Chief Executive Officer & Director
Gary W. ChristiansonChief Operating Officer
Julia Marie EastlandCFO, Secretary & VP-Corporate Development
Scott Robert PetersonChief Scientific Officer
Diana F. HausmanChief Medical Officer